Metagenomi Therapeutics (MGX) Operating Leases (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Operating Leases of $33.1 million for Q1 2026, down 14.81% year-over-year from $38.8 million in Q1 2025, and down 4.48% quarter-over-quarter from $34.6 million in Q4 2025.
Metagenomi Therapeutics (MGX) Operating Leases (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Operating Leases for 4 consecutive years, with $33.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 14.81% year-over-year to $33.1 million; the TTM figure through Mar 2026 stood at $33.1 million (down 14.81% YoY), while the FY2025 annual figure was $34.6 million, down 13.82% from the prior year.
- Operating Leases retreated to $33.1 million in Q1 2026 per MGX's latest filing, from $34.6 million in the prior quarter.
- Across five years, Operating Leases topped out at $44.8 million in Q4 2023 and bottomed at $33.1 million in Q1 2026.
- Historically, Operating Leases has averaged $39.3 million across 4 years, with a median of $39.5 million in 2024.
- Annual changes were most pronounced in 2024 — Operating Leases slipped 10.3% — and 2026, when it slipped 14.81%.
- Metagenomi Therapeutics' Operating Leases stood at $44.8 million in 2023, then dropped by 10.3% to $40.2 million in 2024, then declined by 13.82% to $34.6 million in 2025, then slipped by 4.48% to $33.1 million in 2026.
- Business Quant data shows MGX's Operating Leases at $33.1 million in Q1 2026, $34.6 million in Q4 2025, and $36.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.49 Mn |
| Mar 31, 2026 | 33.08 Mn |
| Dec 31, 2025 | 34.63 Mn |
| Sep 30, 2025 | 36.09 Mn |
| Jun 30, 2025 | 37.48 Mn |
| Mar 31, 2025 | 38.83 Mn |
| Dec 31, 2024 | 40.19 Mn |
| Sep 30, 2024 | 41.38 Mn |
| Jun 30, 2024 | 42.55 Mn |
| Mar 31, 2024 | 43.68 Mn |
| Dec 31, 2023 | 44.80 Mn |